RNA Formulation Videos

  1. Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery 4/14/2022

    Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.

  2. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

    In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

  3. Democratizing RNA Nanotherapeutics 4/14/2022

    This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.

  4. In What Ways Are We Underestimating LNP Complexity Today? 12/4/2024

    As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

  5. Transforming Nanoparticle Formulations From Bench To Commercial Scale 11/11/2025

    Unlock seamless transition from lab-scale nanoparticle research to commercial production. Learn how scalable turbulent-jet mixing ensures precise, uniform, and reproducible formulation results.

  6. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

  7. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  8. Complexity, Biodegradability, And Scale In Active LNP R&D 2/24/2026

    NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk us through the challenges active delivery strategies pose, particularly as it relates to receptor selection, and the emerging technologies/tools that can help us achieve greater delivery specificity to the target cell type.

  9. mRNA's Future Beyond The COVID Vaccines 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.

  10. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.